People news: Savient and Lilly Oncology

Share this article:
John Johnson, SVP and president of Lilly Oncology, has resigned from the company effective January 28. He will join New Jersey-based Savient Pharmaceuticals as the company's CEO, effective January 31. Johnson's decision to resign was “driven by personal and family considerations,” according to a Lilly statement. Johnson, formerly CEO of ImClone, became SVP and president of Lilly Oncology following Lilly's acquisition of ImClone in 2008. Prior to ImClone, Johnson served as company group chairman of J&J's worldwide biopharmaceuticals unit.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

Email Newsletters

MM&M inVISION